Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin Maintenance After Allo-HCT for CD30+ Malignancies
NCT01620229Phase 2Withdrawn
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jun 2013
- Primary completion
- Apr 2014
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in Hodgkin lymphoma (HL) and CD30-positive lymphoid malignancy, sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Incidence of durable hematopoietic engraftment at Day 84. Planned start Jun 2013; status: withdrawn.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)CD30-positive lymphoid malignancy
Beyond the preview
Go deeper on NCT01620229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01620229.